Your browser doesn't support javascript.
loading
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst, Mette S; van der Voort, Anna; van Werkhoven, Erik D; Mandjes, Ingrid A; Kemper, Inge; Dezentjé, Vincent O; Oving, Irma M; Honkoop, Aafke H; Tick, Lidwine W; van de Wouw, Agnes J; Mandigers, Caroline M; van Warmerdam, Laurence J; Wesseling, Jelle; Vrancken Peeters, Marie-Jeanne T; Linn, Sabine C; Sonke, Gabe S.
Afiliación
  • van Ramshorst MS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • van der Voort A; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • van Werkhoven ED; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Mandjes IA; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Kemper I; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Dezentjé VO; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, Netherlands.
  • Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, Netherlands.
  • Honkoop AH; Department of Medical Oncology, Isala, Zwolle, Netherlands.
  • Tick LW; Department of Medical Oncology, Maxima Medical Center, Eindhoven, Netherlands.
  • van de Wouw AJ; Department of Medical Oncology, VieCuri Medical Center, Venlo, Netherlands.
  • Mandigers CM; Department of Medical Oncology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands.
  • van Warmerdam LJ; Department of Medical Oncology, Catharina Cancer Centre, Eindhoven, Netherlands.
  • Wesseling J; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Vrancken Peeters MT; Department of Surgery, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Linn SC; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pathology, University Medical Centre, Utrecht, Netherlands.
  • Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: g.sonke@nki.nl.
Lancet Oncol ; 19(12): 1630-1640, 2018 12.
Article en En | MEDLINE | ID: mdl-30413379
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Epirrubicina / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Terapia Neoadyuvante / Anticuerpos Monoclonales Humanizados / Trastuzumab Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Epirrubicina / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Terapia Neoadyuvante / Anticuerpos Monoclonales Humanizados / Trastuzumab Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos